Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC

Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK
CDK4/6 inhibitors and endocrine therapy in elderly female patients with advanced hormone receptor positive HER-2 negative BC ( Dr Renu Ragupathi - University Hospitals Dorset, Bournemouth, UK )
1 Nov 2024

Fracture risk increases following cancer therapies for advanced prostate cancer

Dr Grace Lu-Yao - Thomas Jefferson University, Philadelphia, USA
Fracture risk increases following cancer therapies for advanced prostate cancer ( Dr Grace Lu-Yao - Thomas Jefferson University, Philadelphia, USA )
1 Nov 2024

Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer

Dr Yue Zhao - University Hospital of Cologne, Cologne, Germany
Unlocking the potential of liquid biopsy applications in personalised care for older adults with cancer ( Dr Yue Zhao - University Hospital of Cologne, Cologne, Germany )
1 Nov 2024

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients

Prof Meletios Dimopoulos - University of Athens, Athens, Greece
Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens,  Athens, Greece )
31 Oct 2024

Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM

Prof Meletios Dimopoulos - University of Athens, Athens, Greece
Daratumumab-based maintenance regimens show favourable responses in transplant-eligible NDMM ( Prof Meletios Dimopoulos - University of Athens,  Athens, Greece )
31 Oct 2024

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting

Prof Meletios Dimopoulos - University of Athens, Athens, Greece
Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting ( Prof Meletios Dimopoulos - University of Athens,  Athens, Greece )
31 Oct 2024

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway
Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )
31 Oct 2024

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA
Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )
31 Oct 2024

Use of bispecifics and CAR T cells in South America

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA
Use of bispecifics and CAR T cells in South America ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )
30 Oct 2024

Tailored to fit: New approaches in transplant-ineligible NDMM

Prof Xavier Leleu - CHU de Poitiers, Poitiers, France
Tailored to fit: New approaches in transplant-ineligible NDMM ( Prof Xavier Leleu - CHU de Poitiers, Poitiers, France )
30 Oct 2024

Advancements in minimal residual disease detection in myeloma

Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada
Advancements in minimal residual disease detection in myeloma ( Dory Abelman, PhD Candidate - University of Toronto, Ontario, Canada )
30 Oct 2024

Novel biomarkers in myeloma: CTCs and cfDNA

Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain
Novel biomarkers in myeloma: CTCs and cfDNA ( Dr Bruno Paiva - Clinica Universidad de Navarra, Pamplona, Spain )
30 Oct 2024